Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
International Society for Gastrointestinal Hereditary Tumours |
RCV000075884 | SCV000106900 | likely benign | Lynch syndrome | 2013-09-05 | reviewed by expert panel | research | Multifactorial likelihood analysis posterior probability 0.001-0.049 |
Mendelics | RCV000987158 | SCV001136387 | benign | Colorectal cancer, hereditary nonpolyposis, type 2 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001017839 | SCV001178996 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-04-02 | criteria provided, single submitter | clinical testing | The p.A282G variant (also known as c.845C>G), located in coding exon 10 of the MLH1 gene, results from a C to G substitution at nucleotide position 845. The alanine at codon 282 is replaced by glycine, an amino acid with similar properties. This alteration has been detected in several individuals with colorectal cancer (Shin YK et al. Hum. Mutat., 2004 Oct;24:351; Roh SA et al. J. Korean Med. Sci., 2003 Jun;18:387-91). In addition, two studies based on in silico model predictions showed this alteration to be both benign and pathogenic, and a third study showed that this alteration may have some impact on splicing (van der Velde KJ et al. Hum. Mutat., 2015 Jul;36:712-9; Lucci-Cordisco E et al. Cancer Biomark, 2006;2:11-27; Soukarieh O et al. PLoS Genet., 2016 Jan;12:e1005756). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |